Pfizer probably did more than any other company to help the world normalize from the pandemic, and it reaped a financial windfall from its twin Covid-19 franchise—the top-selling vaccine and the leading treatment, Paxlovid.
The world, however, has stopped worrying about Covid—and Pfizer (ticker: PFE) is paying the price. The sales of its two Covid blockbusters may decline over 60% in 2023, after generating a combined $57 billion in revenue during 2022. And there is considerable uncertainty about demand for both in the coming years.
Source: finance.yahoo.com
Related posts:
Taylor Swift showed her financial savvy when she avoided a FTX deal. She puts her money in a niche t...
A rolling debt transfer is coming: 'Debt does not miraculously disappear'
4 Colossal Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Occidental, Devon, and 7 Other Energy Stocks That Look Particularly Cheap
Here's how much the typical baby boomer has saved for retirement — how do you stack up right now?